论文部分内容阅读
目的:探讨αL岩藻糖苷酶AFU对原发性肝癌诊断价值。方法:应用分光比色法测定36例原发性肝癌(PHC)、5例肝硬变、4例肝良性占位病变、40例消化系统恶性肿瘤和40例正常健康人血清αL岩藻糖苷酶(AFU)活性值。结果:PHC组血清AFU活性显著高于其余各组(P<001);AFU对PHC诊断敏感度、特异性、准确度分别为806%、899%、872%,阳性预报率、阴性预报率分别为762%、920%;AFU与AFP联合检测可使PHC诊断阳性率提高到917%。结论:AFU可作为原发性肝癌的血清标志物,对AFP阴性病例尤有价值。
Objective: To investigate the diagnostic value of αLfucosidase AFU in primary liver cancer. Methods: Spectrophotometric method was used to determine 36 cases of primary liver cancer (PHC), 5 cases of cirrhosis, 4 cases of benign liver lesions, 40 cases of digestive system malignancies, and 40 cases of normal healthy human serum α-L Algalase (AFU) activity value. Results: The serum AFU activity in PHC group was significantly higher than that in other groups (P<001). The sensitivity, specificity, and accuracy of AFU in diagnosis of PHC were 80.6%, 89.9%, and 87.4%, respectively. Positive predictive rate and negative predictive rate were 76. 2% and 92.0%, respectively; combined detection of AFU and AFP increased the positive rate of PHC diagnosis to 91.7%. Conclusion: AFU can be used as a serum marker for primary hepatocellular carcinoma, and it is especially valuable for AFP-negative cases.